News from mabvax therapeutics holdings, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 04, 2019, 08:00 ET MabVax Therapeutics and Oncotelic Enter into Merger Discussions

MabVax Therapeutics Holdings, Inc. (OTC Pink: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery...

Dec 13, 2018, 08:00 ET MabVax Therapeutics Engages Objective Capital as Advisor for Exploring Asset Sales

MabVax Therapeutics Holdings, Inc. (OTC Pink: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery...

Nov 28, 2018, 08:00 ET MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement

MabVax Therapeutics Holdings, Inc. (OTC Pink: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...

Oct 16, 2018, 08:00 ET MabVax Therapeutics Audited Financial Statements Reinstated

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Sep 21, 2018, 08:00 ET Delaware Court of Chancery Grants Petition Filed by MabVax Therapeutics

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Sep 11, 2018, 14:44 ET MabVax Therapeutics Files Suit Against Sichenzia Ross Ference LLP, a Law Firm that Formerly Represented the Company in Certain Corporate, Securities, and Securities and Exchange Commission Matters

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Aug 23, 2018, 09:39 ET MabVax Therapeutics Engages New Independent Auditor

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Aug 08, 2018, 16:45 ET MabVax Therapeutics Announces Auditor Resignation

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Aug 03, 2018, 13:37 ET Delaware Court of Chancery Sets Hearing Date On Petition Filed By MabVax Therapeutics

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Aug 01, 2018, 19:47 ET MabVax Therapeutics Announces Board of Director Changes

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Jul 27, 2018, 13:14 ET MabVax Therapeutics Files Delaware Petition

MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the...

Jul 09, 2018, 08:00 ET MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announced they...

Jul 06, 2018, 08:00 ET MabVax Therapeutics' HuMab-5B1 ImmunoPET Imaging Agent MVT-2163 Subject of National Institutes of Health R01 Research Grant Awarded to Memorial Sloan Kettering Cancer Center

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company, announced today that Memorial Sloan Kettering...

Jul 05, 2018, 17:15 ET MabVax Therapeutics Receives Nasdaq Delist Determination

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...

Jul 03, 2018, 08:00 ET MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a...

Jul 02, 2018, 08:30 ET MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...

May 24, 2018, 08:05 ET MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...

May 17, 2018, 08:45 ET MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on...

May 07, 2018, 08:35 ET MabVax Therapeutics Presentation from VirtualInvestorConferences.com Now Available for On-Demand Viewing

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that the May 3rd presentation...

May 03, 2018, 10:45 ET MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...

Apr 18, 2018, 08:30 ET MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, announced today that three poster...

Apr 13, 2018, 04:01 ET MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq's Minimum Stockholders' Equity Requirements

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that it received a letter from ...

Mar 15, 2018, 08:35 ET MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, announced today that it will present three...

Feb 28, 2018, 07:30 ET MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to...

Feb 15, 2018, 07:30 ET MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of...